ORINDA, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) — MacKenzie Realty Capital, Inc. (Nasdaq: MKZR) (“MacKenzie” or the “Company”) today announced its financial results for the year ended June 30, 2026 and announced that its Board has temporarily suspended the Preferred Share Repurchase Program while it explores strategic transactions such as reverse takeovers. 

Key Financial Highlights:
Operating Results for the Year Ended June 30, 2026:

  • Net revenues for year ended June 30, 2026, were $20.01 million, a decrease of 9% from $22.06 million in the same period of 2025.
  • Net operating loss was $15.61 million, a decrease of 33% as compared to a net operating loss of $23.46 million in the same period of 2025.
  • Net loss was $14.13 million, a decrease of 41% compared to a $23.97 million loss in the same period of 2025.

Robert Dixon, CEO and President of MacKenzie Realty Capital, stated, “While net revenues declined 9% compared to the prior year (primarily due to approximately $3.0 million of lease termination income recognized in the 2025 period), the annual results were in line with our internal expectations, and the Company achieved meaningful reductions in net operating loss and net loss. We remain focused on executing our growth initiatives while maintaining financial discipline which we believe will deliver sustained value creation over the long term.”

Board Temporarily Suspends Preferred Share Repurchase Program

To enable the Company to better react to any strategic alternative that may be brought to it by its financial advisor, Maxim Group LLC (“Maxim”), the Board has determined to temporarily suspend the Preferred Share Repurchase Program. The Company’s issuance of common stock in exchange for preferred shares has resulted in additional selling pressure on the Company’s common stock, which the Board believes would make the negotiation of any potential strategic transaction more difficult. The Company continues to review strategic alternatives brought to it by Maxim, and the Board expects to reassess the Preferred Share Repurchase Program in due course. There can be no assurance that the Company will enter into any strategic transaction as a result of these efforts, and the Company undertakes no obligation to provide further updates on its strategic review except as required by applicable law.

About MacKenzie Realty Capital, Inc. 
MacKenzie, founded in 2013, is a West Coast-focused REIT that intends to invest at least 80% of its total assets in real property, and up to a maximum of 20% of its total assets in illiquid real estate securities.  We intend for the real property portfolio to be approximately 50% multifamily and 50% boutique class A office. The current portfolio includes interests in 5 multifamily properties and 8 office properties plus 1 multifamily development.

For more information, please contact MacKenzie at (800) 854-8357. Please visit our website at: http://www.mackenzierealty.com

Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, among others, our ability to remain financially healthy, our expected future growth prospects, , and our ability to successfully complete a transaction resulting from a strategic alternative that may be brought to us by our financial advisor, Maxim. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. In some cases, forward-looking statements can be identified by the use of forward-looking terms such as “anticipate,” “estimate,” “believe,” “continue,” “could,” “intend,” “may,” “plan,” “potential,” “predict,” “should,” “will,” “expect,” “objective,” “projection,” “forecast,” “goal,” “guidance,” “outlook,” “effort,” “target,” “trajectory,” “focus,” “work to,” “attempt,” “pursue,” or the negative of these terms or other comparable terms. However, the absence of these words does not mean that the statements are not forward-looking. These forward-looking statements are based on certain assumptions and analyses made by us in light of our experience and our perception of historical trends, current conditions and expected future developments, as well as other factors we believe are appropriate in the circumstances. For a further discussion of factors that could cause our future results, performance, or transactions to differ significantly from those expressed in any forward-looking statement, please see the section titled “Risk Factors” in annual reports on Form 10-K and quarterly reports on Form 10-Q that we file with the Securities and Exchange Commission from time to time. 

GLEN ALLEN, Va., Sept. 30, 2026 (GLOBE NEWSWIRE) — Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that the Company’s Compensation Committee has granted a new employee stock option to purchase 155,446 shares of common stock as an inducement to such person becoming an employee of the Company.

The option award has an exercise price of $4.22 per share, the closing price of the Company’s common stock on September 25, 2026, the effective date of grant and has a ten-year term. The option award will vest over four years, with 25% vesting on the first anniversary of the grant date and the remainder vesting in equal monthly installments thereafter, subject to the recipient’s continued service through each applicable vesting date.

The above grant was approved by the Company’s Compensation Committee and was made as an inducement material to the employee entering into employment with Adial. The grant was made outside of the Company’s equity incentive plans and in reliance on the employment inducement exception to shareholder approval provided under Nasdaq Listing Rule 5635(c)(4), which requires public announcement of inducement awards.

About Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals, a clinical-stage biopharmaceutical company, has historically focused on the development of treatments for addictions and related disorders. In June 2026, the Company acquired Azora Therapeutics, a biopharmaceutical company focused on treating autoimmune diseases, including ulcerative colitis (“UC”). Following the acquisition of Azora, the Company’s focus has shifted to the treatment of serious inflammatory diseases, and its lead program is AT177, which is being studied for the treatment of UC. AT177 is a fully synthetic, patented, oral AhR agonist designed to restore mucosal immune homeostasis at the site of disease with minimal systemic exposure. Its active ingredient is a prodrug of indirubin, the most potent AhR agonist within indigo naturalis, a botanical extract with best-in-category clinical efficacy in UC. In preclinical studies, AT177 demonstrated robust local colonic AhR activation with markedly limited systemic exposure. AT177 is currently in IND-enabling studies, with an investigational new drug (“IND”) filing planned for the first half of 2027, initiation of a Phase 1a single- and multiple-ascending-dose (“SAD/MAD”) clinical trial planned to commence in the second half of 2027, followed by a Phase 1b proof-of-concept study in UC patients. Additional information is available at www.adial.com.

Cautionary Note Regarding Forward-Looking Statements

This communication contains certain “forward-looking statements” within the meaning of the U.S. federal securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. The forward-looking statements include, but are not limited to, statements regarding the vesting of the inducement awards and IND filing planned for the first half of 2027, initiation of a Phase 1a single- and multiple-ascending-dose clinical trial planned to commence in the second half of 2027, followed by a Phase 1b proof-of-concept study in UC patients. Any forward-looking statements included herein reflect the Company’s current views, and they involve certain risks and uncertainties, including, among others, the Company’s ability to pursue its regulatory strategy; the Company’s ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements; the Company’s ability to develop strategic partnership opportunities and maintain collaborations; the Company’s ability to obtain or maintain the capital or grants necessary to fund its research and development activities; the Company’s ability to complete clinical trials on time and achieve desired results and benefits as expected; regulatory limitations relating to the Company’s ability to promote or commercialize its product candidates for specific indications; acceptance of the Company’s product candidates in the marketplace and the successful development, marketing or sale of its products; the Company’s ability to maintain its license agreements; the continued maintenance and growth of the Company’s patent estate and its ability to retain its key employees or maintain the Company’s Nasdaq listing. These risks should not be construed as exhaustive and should be read together with the other cautionary statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, subsequent Quarterly Reports on Form 10-Q and current reports on Form 8-K filed with the Securities and Exchange Commission. These risks should not be construed as exhaustive and should be read together with the other cautionary statements contained in such reports. Any forward-looking statement speaks only as of the date on which it was initially made. The Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required by law.

Contact:

Mike Moyer
Managing Director,
LifeSci Advisors, LLC
Phone: (617) 328-4326
Email: mmoyer@lifesciadvisors.co

TORONTO, Sept. 30, 2026 (GLOBE NEWSWIRE) — Xanadu Quantum Technologies Limited (“Xanadu”; NASDAQ/TSX: XNDU), a leading photonic quantum computing company, today announced that Rafal Janik, Xanadu’s Chief Operating Officer, has entered into an automatic securities disposition plan (the “Plan”) to sell Class B Subordinate Voting Shares of Xanadu (“Class B Shares”) held directly by Mr. Janik. The Plan has been adopted in accordance with applicable securities laws and Xanadu’s internal policies. Sales of Class B Shares under the Plan are eligible to commence on or after December 29, 2026.

The Plan was entered into when Mr. Janik was not in possession of material non-public information regarding Xanadu and permits trades to be made in accordance with pre-arranged instructions given when Mr. Janik is not in possession of material non-public information regarding Xanadu. The Plan provides for the sale of up to 312,914 Class B Shares and will terminate no later than December 31, 2027. The Class B Shares that could potentially be disposed of under the Plan may include Class B Shares, currently held, directly or indirectly, by Mr. Janik and Class B Shares issued to Mr. Janik upon vesting and/or exercise of options and restricted share units granted to Mr. Janik as compensation for his services as Chief Operating Officer. Sales of Class B Shares under the Plan will be effected by an independent securities broker in accordance with the trading parameters, price and other restrictions and instructions set out in the Plan. The Plan has been authorized and established in the form approved by Xanadu and contains meaningful restrictions on the ability of Mr. Janik to modify, suspend or terminate the Plan.

This announcement is made and will be available on SEDAR+ at www.sedarplus.ca pursuant to the recommended practices set forth in Staff Notice 55-317 Automatic Securities Disposition Plans of the Canadian Securities Administrators. Information regarding the Plan and transactions thereunder, as the case may be, may be accessed on SEDI at www.sedi.ca.

About Xanadu

Founded in 2016, Xanadu is a Canadian photonic quantum computing company with the mission to build quantum computers that are useful and available to people everywhere. Xanadu is building fault-tolerant quantum computers using light, with systems designed to compute at room temperature. Xanadu develops both hardware and software, including PennyLane, its open-source quantum computing platform. Xanadu is the first pure-play photonic quantum computing company to list on public markets (Nasdaq/TSX: XNDU) and is recognized globally for its breakthroughs in scalable quantum technologies. Visit xanadu.ai or follow on X @XanaduAI.

Contacts

Press Contact:press@xanadu.ai
Investor Relations:investors@xanadu.ai

Not for distribution to U.S. news wire services or for dissemination in the United States

Toronto, Ontario, Sept. 30, 2026 (GLOBE NEWSWIRE) — Avante Corp. (TSX.V: XX) (“Avante” or the “Company”) is pleased to announce that the Company’s five nominees set forth in the Company’s management information circular dated August 25, 2026 (the “Circular”), being Daniel Argiros, Wendy Teramoto, Robert Klopot, Emmanuel Mounouchos and Jonathan Pollack, were all elected as directors of the Company at the annual general and special meeting of shareholders held today (the “Meeting”). Each of the directors elected at the Meeting will hold office until the next annual general meeting of the Company or until their successor is duly elected or appointed, unless their post is vacated earlier.

At the Meeting, shareholders also approved the appointment of Deloitte LLP as the auditor of the Company until the close of the next annual general meeting, as well as the ratification of the Company’s stock option plan. Shareholders did not approve any of Shareholder Proposal One, Shareholder Proposal Two, Shareholder Proposal Three, Shareholder Proposal Four or Shareholder Proposal Five, each as described in Schedule D of the Circular.

Further information with respect to the matters considered at the Meeting can be found in the Circular, which is available under Avante’s issuer profile on SEDAR+ at www.sedarplus.ca.

Detailed voting results with respect to the matters considered at the Meeting are set out in the tables below.

Election of Directors

Nominee Votes For % of Votes For Votes Withheld % of Votes Withheld
Daniel Argiros 12,877,690 60.0% 8,586,436 40.0%
Wendy Teramoto 12,877,690 60.0% 8,586,436 40.0%
Robert Klopot 12,877,690 60.0% 8,586,436 40.0%
Emmanuel Mounouchos 12,779,290 59.5% 8,684,836 40.5%
Jonathan Pollack 20,918,935 97.5% 545,191 2.5%


Appointment of Auditor

Votes For % of Votes For Votes Withheld % of Votes Withheld
14,226,030 66.1% 7,308,318 33.9%


Ratification of Stock Option Plan

Votes For % of Votes For Votes Against % of Votes Against
12,747,290 59.4% 8,716,836 40.6%


Shareholder Proposals

Proposal Votes For % of Votes For Votes Against % of Votes Against
Shareholder Proposal One 9,776,876 45.5% 11,687,250 54.5%
Shareholder Proposal Two 9,776,876 45.5% 11,687,250 54.5%
Shareholder Proposal Three 9,136,613 42.6% 12,327,513 57.4%
Shareholder Proposal Four 9,136,613 42.6% 12,327,513 57.4%
Shareholder Proposal Five 9,136,613 42.6% 12,327,513 57.4%

Emmanuel Mounouchos, Founder, Chief Executive Officer and Board Chair of Avante, commented, “Thank you to our shareholders for their continued support. We look forward to welcoming you to next year’s annual meeting, which will be held both in person and online, where you can meet our leadership, see our technology in action and have your questions answered directly.”

About Avante Corp.

Avante Corp. is a Toronto-based leading provider of security personnel and technology-enabled security solutions for residential and commercial clients. Avante’s mission is to deliver an elevated level of security globally, with a white-glove approach for high-net-worth families and corporations alike, through advanced solutions and methods for detecting conditions requiring immediate response. The Company has developed a diversified security platform that leverages cutting-edge technology to deliver superior security services. With an experienced team and a proven track record of solid growth, Avante is taking steps to build a broad portfolio of security businesses and solutions for its customers through organic growth complemented by strategic acquisitions. Avante acquires, manages, and develops industry-leading companies that provide specialized, mission-critical solutions to address the security risks faced by its clients. Avante is listed on the TSX Venture Exchange under the ticker “XX”. For more information, please visit www.avantecorp.ca and consider joining our investor email list.

Forward-Looking Statements

This news release may contain “Forward-Looking Information” as defined by applicable Canadian securities laws. Forward-Looking Information is based on various estimates and assumptions that, while deemed reasonable by management, are inherently subject to significant business, economic, and competitive uncertainties and contingencies. Forward-Looking Information is typically identified by the use of forward-looking words such as “may,” “should,” “will,” “could,” “intend,” “estimate,” “plan,” “anticipate,” “expect,” “believe,” or “continue,” along with the negative forms or similar terms, and includes statements in this press release related to Avante’s next annual meeting of shareholders. These involve known and unknown risks, uncertainties, and factors that could cause actual results, performance, or achievements to differ materially from the estimated or implied results, performance, or achievements described or forecasted in such information. Such statements are not guarantees of future performance. Avante’s comments expressed or implied by Forward-Looking Information are subject to numerous risks, uncertainties, and conditions, many of which are beyond Avante’s control, and undue reliance should not be placed on them. Forward-Looking Information is entirely qualified by inherent risks and uncertainties, including adverse market conditions impacting results; the possibility of future results differing from historical performance; market competition affecting business, results, and financial condition; and other risk factors listed in documents filed by Avante on its profile on SEDAR+ at www.sedarplus.ca, including its annual Management’s Discussion and Analysis. Except as required by applicable securities laws, Avante does not undertake any obligation to update or revise any Forward-Looking Information, whether due to new information, events, or otherwise.

Avante Corp.

For further information:
Emmanuel Mounouchos
CEO, Chairman, and Founder
(416) 923-6984
manny@avantesecurity.com

Pardeep Sangha
Investor Relations
(604) 572-6392
pardeep@angadcapital.com

Neither the TSX Venture Exchange Inc. (“Exchange”) nor its regulation services provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Oculis Announces Resignation of Lionel Carnot from Board of Directors

ZUG, Switzerland, September 30, 2026 — Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announces that director Lionel Carnot will be resigning from the Board of Directors, effective today, after nearly a decade of dedicated service since 2017.

Anthony Rosenberg, Chair of the Board, remarked: “On behalf of the Board and the entire Oculis team, we wish to extend our sincere gratitude to Lionel for his invaluable service, leadership and guidance over nearly a decade, covering a transformative period for Oculis, where it evolved from a private startup company to a publicly listed late-stage biopharmaceutical company. His contributions to the Board and Oculis have been instrumental in our growth and evolution to become an emerging leader in neuro-ophthalmology.”

Lionel Carnot remarked: “It has been a privilege to work alongside Oculis’ talented and dedicated team committed to addressing significant unmet medical needs and advance innovative solutions for patients suffering from ophthalmic and neuro-ophthalmic diseases. As the Company enters its next stage of growth, this is a timely point for me to step down and focus on other commitments. As an investor, I remain confident in the potential of Oculis’ pipeline and look forward to the Company achieving important milestones in the years ahead.”

Mr. Carnot’s departure is purely a personal decision and is not the result of any disagreement with the Company on any matter relating to its operations, policies, or practices. Following the resignation, the Board will consist of eight members and the Remuneration Committee, of which Mr. Lionel served as chair, will consist of Geraldine O’Keeffe as chair and Gregory Perry and Robert Warner as members. Pursuant to Swiss law, the vacancy on the Board resulting from Mr. Carnot’s resignation may only be filled at a future annual or special general meeting. Oculis will begin identifying a successor for Mr. Carnot and will provide updates as appropriate.

-ENDS-

About Oculis

Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology. Oculis’ highly differentiated late-stage clinical pipeline focuses on two core product candidates. Privosegtor is a breakthrough neuroprotective candidate in the PIONEER program, which consists of studies intended to support registration plans for treatment of optic neuropathies, including optic neuritis (ON) and non-arteritic anterior ischemic optic neuropathy (NAION). Privosegtor also has potential to be developed for additional indications in other neuro-ophthalmic and neuro-axonal diseases. Licaminlimab is a novel, topical anti-TNFα in a registrational trial, and is being developed with a genotype-based approach for treating patients with dry eye disease (DED). Headquartered in Switzerland with operations in the U.S., Iceland and Switzerland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.
        
For more information, please visit: www.oculis.com

Oculis Contact
Ms. Sylvia Cheung, CFO
sylvia.cheung@oculis.com

Investor Relations
LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com

Media Relations
ICR Healthcare
Amber Fennell
oculis@icrhealthcare.com

MEXICO CITY, Sept. 30, 2026 (GLOBE NEWSWIRE) — Grupo Aeroméxico S.A.B. de C.V. (NYSE: AERO & BMV: AERO) (“Aeroméxico”) will hold a live conference call and webcast on Tuesday, October 20, 2026, at 8:00 a.m. Mexico City Time (10:00 a.m. Eastern Time) to discuss its third quarter 2026 financial results.

During the call, management will review the company’s operating and financial performance for the period, highlighting key business drivers, recent developments, and strategic initiatives that shaped Aeroméxico’s results throughout the third quarter. The event will also include a Q&A session for investors and analysts.

A live webcast of this event will be available at ir.aeromexico.com and an online replay will be available shortly after the webcast is complete.

The company’s third quarter 2026 earnings results will be released after the market closes on Monday, October 19, 2026.

Conference Call Details

Date: Tuesday, October 20, 2026

Time: 8:00 a.m. Mexico City / 10:00 a.m. (ET)

Webcast link: https://edge.media-server.com/mmc/p/uh5yer4m

Dial-in link: https://register-conf.media-server.com/register/BIce2042e6b22d45d587f891c8178a6137

Contact:  
Investor Relations  aminvestorrelations@aeromexico.com
Corporate Communications amcomunicacioncorporativa@aeromexico.com


About Grupo Aeroméxico

Grupo Aeroméxico, S.A.B. de C.V., is a holding company whose subsidiaries are engaged in commercial aviation in Mexico and in the promotion of passenger loyalty programs. Aeroméxico, Mexico’s global airline, operates primarily out of Terminal 2 of the Mexico City International Airport. Its destination network extends across Mexico, the United States, Canada, Central America, South America, Asia, and Europe. Aeroméxico’s current operating fleet includes Boeing 787 and 737 aircraft, as well as Embraer 190. Aeroméxico is a founding member of SkyTeam, an alliance celebrating 25 years and offering connectivity across more than 145 countries through its 18 partner airlines.

NEW YORK, Sept. 30, 2026 (GLOBE NEWSWIRE) — Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a clinical stage biotechnology company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that it will participate in the Foundation for Prader-Willi Research (FPWR) 2026 Research Symposium, October 7-8, and the PWS Family Conference, October 9-10, at the Marriott Philadelphia Downtown.

The FPWR meeting brings together families, caregivers, clinicians, researchers, and industry to share the latest in PWS research and care. Bright Minds’ participation reflects the Company’s commitment to developing a therapy that addresses both hyperphagia and the neurobehavioral symptoms of PWS, and to keeping the PWS community closely involved as its clinical program advances.

“There is no therapy today that adequately addresses the full burden of Prader-Willi Syndrome: the relentless hunger and the behavioral and psychiatric challenges that families live with every day,” said Ian McDonald, Chief Executive Officer and Co-founder of Bright Minds Biosciences. “The FPWR community has shaped how we think about this disease, from the outcome measures we use to the way we design our studies. We are proud to support this year’s meeting and to spend time with the families and researchers who are driving progress in PWS. Our NOVA study of BMB-101 is under way. We believe selective 5-HT2C agonism has the potential to address the underlying biology of PWS rather than a single symptom.”

Bright Minds’ PWS Program

Individuals with PWS have reduced levels of functional 5-HT2C receptors, which are central regulators of appetite, satiety, and behavior. Bright Minds is developing highly selective, Gq-biased 5-HT2C agonists designed to restore signaling through this pathway while avoiding the receptor desensitization and 5-HT2B-related cardiac liabilities that limited earlier serotonergic agents.

BMB-101 is being evaluated in NOVA, a randomized, double-blind, placebo-controlled Phase 2a study assessing the effect of BMB-101 on hyperphagia (primary endpoint: change from baseline in the Hyperphagia Questionnaire for Clinical Trials, HQ-CT), PWS-associated behaviors, and safety and tolerability over a 16-week treatment period, with an optional open-label extension.

In November 2025, the Company expanded its Scientific Advisory Board with four global PWS experts, including Theresa V. Strong, PhD, a founding member of FPWR and its Director of Research Programs; Jennifer L. Miller, MD, University of Florida; Elizabeth Roof, H.S.P., M.A., Vanderbilt University; and Tania Markovic, MBBS PhD FRACP, Royal Prince Alfred Hospital, Sydney.

About Prader-Willi Syndrome

Prader-Willi syndrome (PWS) is a rare genetic neurodevelopmental disorder resulting from abnormal gene expression on chromosome 15, affecting approximately one in every 15,000 live births. The hallmark feature of PWS is hyperphagia, a chronic, life-threatening condition marked by an unrelenting feeling of hunger, obsessive thoughts about food, and a lack of normal satiety. Hyperphagia is associated with serious health risks, including choking, stomach rupture, and accidental death related to food-seeking, as well as obesity, type 2 diabetes, and cardiovascular disease. Individuals with PWS also experience significant neurobehavioral challenges, including emotional dysregulation, compulsivity, temper outbursts, and cognitive impairment. Currently available therapies address hyperphagia only; there are no approved treatments for the neurobehavioral symptoms of PWS.

Corporate Update

The Company also announces that it has entered into a mutual rescission and release agreement with an officer of the Company rescinding the officer’s prior exercise of stock options in respect of 44,500 common shares. The 44,500 shares issued on that exercise will be returned to treasury and cancelled, the aggregate exercise price will be refunded to the officer, and the options are restored on their original terms, including exercise price, vesting schedule and expiry date, under the Company’s share option plan. No other options are affected.

About Bright Minds Biosciences

Bright Minds is a biotechnology company developing innovative treatments for patients with neurological and psychiatric disorders. Our pipeline includes novel compounds targeting key receptors in the brain to address conditions with high unmet medical need, including epilepsy, Prader-Willi Syndrome, depression, and other CNS disorders. Bright Minds is focused on delivering breakthrough therapies that can transform patients’ lives.

Bright Minds has developed a unique platform of highly selective serotonergic agonists exhibiting selectivity at different serotonergic receptors. This has provided a rich portfolio of NCE programs within neurology and psychiatry.

Contact Information

Investor Relations
Lisa M. Wilson
T: 212-452-2793
E: lwilson@insitecony.com

Alex Vasilkevich
Chief Operating Officer
Bright Minds Biosciences Inc.
T: 414-731-6422
E: alex@brightmindsbio.com
Website: www.brightmindsbio.com

Forward Looking Information

This news release contains “forward-looking information”. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, or “believes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements in this news release include, without limitation, statements related to the Company’s participation in the FPWR Research Symposium and PWS Family Conference, the Company’s goal of developing a therapy that addresses both hyperphagia and the neurobehavioral symptoms of PWS, the expected design characteristics of the Company’s drug candidates, the conduct, enrolment, design, timeline, endpoints and results of the NOVA study, the potential of selective 5-HT2C agonism to address the underlying biology of PWS, the Company’s broader pipeline development objectives and its ability to deliver breakthrough therapies that can transform patients’ lives, and the completion of the return and cancellation of the 44,500 common shares and the refund of the exercise price described under “Corporate Update”. Such statements represent the Company’s current views with respect to future events and are necessarily based upon a number of assumptions and estimates that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social risks, contingencies and uncertainties. Many factors, both known and unknown, could cause results, performance, or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements. Additional risk factors can also be found in the Company’s public filings under the Company’s SEDAR+ profile at www.sedarplus.ca. Forward-looking statements contained herein are made as of the date of this news release and the Company disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances, management’s estimates or opinions should change, except as required by securities legislation. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements.

The Canadian Securities Exchange has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.

The securities of the Company referred to in this news release have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws. Accordingly, the securities of the Company may not be offered or sold within the United States unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws. This news release does not constitute an offer to sell or a solicitation of any offer to buy any securities of the Company in any jurisdiction in which such offer, solicitation or sale would be unlawful.

– Financing includes leading U.S. biotechnology institutional investors and mutual funds –

LOS ANGELES, CA, Sept. 30, 2026 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (“ImmixBio”, “Company”, “we” or “us” or “IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the closing of its previously announced underwritten registered offering of 11,363,637 shares of its common stock at a public offering price of $11.00 per share. The net proceeds to Immix from the offering, after deducting the underwriting discounts, commissions and other offering expenses, were approximately $117.1 million.

Immix intends to use the net proceeds from this offering to fund NXC-201 development, working capital and general corporate purposes.

J.P. Morgan acted as the sole book-running manager for the offering. The offering included participation from leading U.S. biotechnology institutional investors and mutual funds.

The shares of common stock described above were offered and sold by the Company pursuant to a shelf registration statement on Form S-3 (File No. 333-292665), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on January 9, 2026, and declared effective on January 22, 2026. A prospectus supplement and accompanying prospectus describing the terms of the offering was filed with the SEC and is available on the SEC’s website located at www.sec.gov. Copies of the prospectus supplement and the accompanying prospectus related to this offering may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com. 

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Immix Biopharma, Inc.

Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a global leader in AL Amyloidosis. AL Amyloidosis is a devastating disease where the immune system, that’s supposed to protect, instead produces toxic light chains, clogging up the heart, kidney and liver, causing organ failure and death. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a proprietary CD3ζ, CD8 hinge and binder “digital filter” designed to filter out non-specific activation. NXC-201 teaches the immune system to recognize and eliminate the source of the toxic light chains. NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a potentially registrational design. NXC-201 has been awarded Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA.

Contacts

Mike Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com 

Company Contact

Gabriel Morris, CFO
irteam@immixbio.com 

WISeKey Reports First Half 2026 Financial Results, Accelerates Quantum and Post-Quantum Strategy and Provides Outlook

Schedules Conference Call for Thursday, October 1 at 9:00am ET

  • H1 2026 Unaudited Revenue Up Approximately 116% to $11.4 Million
  • Approximately $495 Million in Cash and Restricted Cash at June 30, 2026
  • SEALSQ Commercial Pipeline Exceeds $225 Million Through 2029
  • FY 2026 Revenue Growth Guidance of 50% to 100% Reaffirmed
  • Shareholders Approved Redomiciliation; Direct Nasdaq and SIX Listing as WISeQey (WQEY) Expected in October
  • Strategic Progress Includes WISeSat and Quantisimo Transactions, Commercial QSOC Deployment, SEALQuantum Expansion and New Swiss Post-Quantum Semiconductor Center

GENEVA, Switzerland – September 30, 2026 – Ad hoc announcement pursuant to Art. 53 LR – WISeKey International Holding Ltd (“WISeKey” or the “Company”) (SIX: WIHN; Nasdaq: WKEY), a global leader in cybersecurity, digital identity, post-quantum semiconductors, quantum technologies and secure satellite infrastructure, today announced its financial results for the six months ended June 30, 2026 (H1 2026) and provided an update on significant strategic developments achieved since the beginning of the year.

H1 2026 Financial Highlights

  • Revenue more than doubled: Revenue rose approximately 116% to approximately $11.4 million, from $5.3 million in H1 2025.
  • Gross profit increased 192% to $5.5 million, compared to gross profit of $1.9 million in H1 2025; gross margin expanded to approximately 48% from 35% in H1 2025.
  • Operating loss was $40.9 million, compared to operating loss of $27.3 million in H1 2025.
  • Net loss was $36.4 million, compared to net loss of $22.3 million in H1 2025.
  • Post-quantum pipeline above $100 million: The commercial pipeline as of September 22, 2026, at subsidiary SEALSQ Corp (Nasdaq: LAES) (“SEALSQ”) exceeds $225 million through 2029 and contains more than $100 million associated with the Company’s Post-Quantum projects, including the QS7001 and QVault TPM. It reflects rising demand as governments, enterprises and critical infrastructure operators prepare to move to quantum-resistant cryptography. These figures represent management estimates and are subject to risks such as conversion risk, customer validation, technical integration and other commercial risks.
  • Over $495 million in cash and restricted cash and minimal debt: At June 30, 2026, the Group held approximately $495 million in cash and restricted cash and had minimal debt.
  • Funding the next phase of growth: This financial strength lets WISeKey keep investing in post-quantum semiconductor commercialization, quantum technologies, sovereign infrastructure and strategic acquisitions, with a long-term investment horizon.
  • FY 2026 guidance reaffirmed: WISeKey expects FY 2026 revenue growth of 50% to 100% year over year.

Carlos Moreira, Founder, Chairman and Chief Executive Officer of WISeKey, said: “2026 is the year the technologies and investments we have built over many years are coming together as one commercial ecosystem, and WISeKey is entering the most important commercialization phase in its history. First-half revenue grew approximately 116%, and we ended June with approximately $495 million in cash and restricted cash and minimal debt. That gives us a strong financial foundation to execute our strategy.

“Our momentum continued into the third quarter. Shareholders approved our redomiciliation, which clears the way for a direct listing on Nasdaq. We advanced the WISeSat and Quantisimo transactions, began commercializing our Quantum Spatial Orbital Cloud, and signed an agreement with the Canton of Jura to develop a sovereign post-quantum semiconductor center in Switzerland.

“Our priorities are now clear and measurable: convert the SEALSQ pipeline into revenue, bring our post-quantum products into volume production, complete the WISeSat and Quantisimo transactions, and expand our sovereign semiconductor infrastructure. Looking beyond 2026, we are building a group in which WISeKey, SEALSQ, WISeSat, and Quantisimo can each grow as focused businesses while remaining connected through one trusted infrastructure. From silicon to qubits, from identity to AI, and from Earth to space, our mission is unchanged: to provide the Root of Trust for the next generation of the digital economy.”

STRATEGIC DEVELOPMENTS

WISeKey Redomiciliation and Planned Direct Nasdaq Structure

WISeKey advanced its strategy to simplify its corporate structure and strengthen its access to U.S. and international capital markets. On June 26, 2026, WISeKey signed a merger agreement to move the domicile of its holding company from Switzerland to the British Virgin Islands. WISeKey’s British Virgin Islands subsidiary, WISeQey Corp. (formerly known as WISeKey International Corp., “WISeQey”) filed a registration statement on Form F-4 with the U.S. Securities and Exchange Commission on July 16, 2026, and the SEC declared it effective on July 31, 2026. At an Extraordinary General Meeting held on September 9, 2026, shareholders approved the redomiciliation and the related merger agreement. On September 16, 2026, the subsidiary, which will become the Group’s new parent company, changed its name to WISeQey Corp.

The redomiciliation is expected to take effect on October 1, 2026, with WISeQey ordinary shares expected to begin trading under the ticker “WQEY” on or about October 5, 2026 on both the Nasdaq Global Market and the SIX Swiss Exchange, which will remain the primary listing. The WISeQey ordinary shares will trade directly on Nasdaq, replacing WISeKey’s existing American Depositary Shares and providing the Group with a more streamlined U.S. capital markets presence while preserving its international footprint. WISeQey’s operational headquarters and place of effective management will remain in Switzerland, and the Group’s businesses and operations are not expected to change. Completion of the redomiciliation remains subject to the remaining closing conditions and the applicable Swiss and British Virgin Islands procedures.

This simplified structure, together with the planned independent listings of WISeSat and Quantisimo, is designed to give investors clearer visibility into the value and performance of each of the Group’s technology platforms.

Quantisimo: Creating a Quantum Technology Pure-Play

In June 2026, WISeKey and SEALSQ established Quantisimo Corp. and executed a non-binding Letter of Intent with GigCapital8 Corp. (Nasdaq: GIW) regarding a potential business combination designed to create a Nasdaq-listed quantum technology company. The initial transaction contemplated an enterprise value of approximately $575 million.

Quantisimo is being designed to bring together selected technologies and investments developed through the SEALQuantum ecosystem, creating a vertically integrated platform spanning quantum computing, photonics, quantum-secure infrastructure and related technologies.

The proposed transaction remains subject to definitive agreements, regulatory review, shareholder approvals and customary closing conditions. The Group is targeting completion of the transaction during the first quarter of 2027, subject to satisfaction of these conditions.

 SEALQUANTUM Sovereign Vertical Stack: Building the Root-to-Qubit Technology Stack

SEALSQ continued to execute its SEALQUANTUM Sovereign Vertical Stack strategy, backed by a targeted allocation of up to $200 million of SEALSQ’s internal capital resources. The strategy aims to build a sovereign, vertically integrated quantum technology stack. It runs from the cryptographic Root of Trust and post-quantum semiconductors through photonics and quantum computing. Key milestones include:

  • SEALSQ completed its acquisition of Miraex SA in Switzerland, adding quantum photonics interconnect technology.
  • SEALSQ invested approximately €15 million in Quobly in France as a lead investor in Quobly’s €115 million Series A financing, and subsequently signed a $5 million commercial agreement.
  • SEALSQ has invested a total of $7.0 million in EeroQ, a U.S.-based quantum computing company.
  • SEALSQ made a majority investment in Wecan Group, and WISeKey is working with Wecan to develop and deploy the next generation of Wecan’s Co-Pilote compliance solution, aiming to integrate post-quantum financial security solutions for the global financial industry.

These assets complement the Group’s in-house semiconductor, PKI and secure infrastructure capabilities into an integrated architecture “Root-to-Qubit.

The WISeKey Quantum RootKey ties these assets together. It extends the Root of Trust that WISeKey has operated under the OISTE Foundation governance model since 1999 into the post-quantum and quantum computing era. WISeKey has begun integrating the Quantum RootKey across the SEALQUANTUM Sovereign Vertical Stack ecosystem, anchoring each asset to a common, quantum-resistant trust layer that spans from chips to qubits.

Post-Quantum Semiconductors Enter Commercialization Phase

SEALSQ’s semiconductor business remains the Group’s technology foundation.

  • In 2026, SEALSQ reached several certification and security milestones for its QS7001 post-quantum secure element and QVault TPM product lines. QS7001 received NIST SP 800-90B Entropy Source Validation, a required step toward FIPS 140-3 and Common Criteria EAL5+ certification. It also completed Common Criteria fault-injection and side-channel resistance testing for both the QS7001 and QVault product lines.
  • Engineering samples of the QVault TPM are now available to customers.
  • SEALSQ separately received NIST FIPS 140-3 Level 3 certification for its VaultIC408 secure element.

WISeKey believes the shift to post-quantum cryptography required by regulators in the United States and Europe is creating a multi-year commercial opportunity for SEALSQ. The Group expects first revenues from its post-quantum products in Q4 2026, with larger contributions anticipated in 2027.

As of June 30, 2026, more than 150 customers and prospects were engaging with SEALSQ’s post-quantum technologies, and more than 30 were actively evaluating or integrating QS7001 and QVault TPM.

As of September 22, 2026, SEALSQ’s commercial pipeline exceeded $225 million through 2029, including more than $100 million tied to post-quantum projects. The pipeline reflects management estimates of potential opportunities. Turning it into recognized revenue will depend on customer qualification, certification, production schedules and other factors.

WISeSat and the Quantum Spatial Orbital Cloud

WISeSat continued progressing toward becoming an independently listed space technology company. Following the public filing of the Form F-4 registration statement in June 2026 and effectiveness of such registration statement in August 2026 in connection with the proposed business combination with Columbus Acquisition Corp. (Nasdaq: COLA), WISeSat continued preparing for the transaction and its intended Nasdaq listing under the ticker SAIQ, subject to shareholder approval, Nasdaq approval and other closing conditions.

At the International Space Summit in Paris in September 2026, WISeKey, SEALSQ and WISeSat presented the commercial Quantum Spatial Orbital Cloud (“QSOC”) initiative.

QSOC is designed to combine WISeSat’s satellite constellation with SEALSQ post-quantum semiconductors, PKI, quantum random-number generation and identity technologies to establish secure and sovereign orbital infrastructure.

The current roadmap contemplates progressive deployment of a constellation of up to 100 satellites through 2033, designed to provide secure communications, quantum-generated trust and post-quantum identity services to governments, defense organizations, financial institutions, critical infrastructure and enterprises.

WISeKey Joins the Hedera Council Network

In September 2026, WISeKey announced that it had joined the Hedera Council network of strategic and community partners, further strengthening the technological foundation supporting its trusted machine-economy strategy.

The collaboration supports WISeKey’s broader objective of combining trusted digital identity, secure hardware, distributed-ledger infrastructure and machine-to-machine transactions. This architecture is particularly relevant to SEALCOIN, where autonomous devices, AI agents, robots and satellites can be provided with verifiable identities and mechanisms for trusted transactions.

New Swiss Post-Quantum Semiconductor and Cybersecurity Center

On September 21, 2026, WISeKey, SEALSQ and the Republic and Canton of Jura signed a Memorandum of Understanding to work together on a Post-Quantum Semiconductor and Cybersecurity Center in the Canton of Jura, Switzerland. The proposed public-private initiative has an indicative investment of approximately CHF 40 million to CHF 60 million over six years.

The Center is intended to give Switzerland its own capabilities to design, personalize, test and securely provision next-generation post-quantum semiconductors, starting with SEALSQ’s QS7001 Quantum Shield. The initiative targets approximately 40 direct jobs within two years, 150 by Year 5 and more than 250 by Year 8, and at least 60% of positions are expected to go to Canton residents.

The Jura project builds on the model of Quantix Edge Security in Murcia, Spain, where WISeKey and SEALSQ are developing sovereign semiconductor design, personalization and cybersecurity capabilities. Together, Murcia and Jura are intended to become key hubs in the WISeKey/SEALSQ Quantum HighwayTM, which links post-quantum semiconductor, quantum, cybersecurity and trusted infrastructure capabilities across multiple regions.

Geneva Quantum Center of Excellence

WISeKey and SEALSQ are also establishing the Geneva Quantum Center of Excellence at the Group’s new headquarters in Pont-Rouge.

The Center is designed as a physical convergence point for the Group’s quantum computing, post-quantum cybersecurity, secure semiconductor, digital identity, satellite, robotics and artificial-intelligence technologies.

The objective is to provide customers, governments, technology partners, regulators and investors with an end-to-end demonstration environment showing how the different components of WISeKey’s trusted technology ecosystem operate together.

FY 2026 GUIDANCE AND OUTLOOK

WISeKey’s outlook statements are based on current expectations. The following statements are forward-looking and actual results could differ materially depending on market conditions and the factors set forth under “Forward Looking Statements” below.

WISeKey reaffirms its FY 2026 revenue growth guidance of 50% to 100% compared with FY 2025.

The Company expects growth during the remainder of 2026 and into 2027 to be supported by several principal drivers:

  • Post-Quantum Semiconductor Commercialization. SEALSQ expects to transition its QS7001, QVault TPM and related post-quantum technologies from development, certification and customer qualification toward commercial production.
  • ASIC and Semiconductor Services. The integration of IC’ALPS provides additional ASIC design capabilities and engineering capacity, expanding the Group’s ability to participate in custom semiconductor and post-quantum design programs.
  • Sovereign Semiconductor Infrastructure. The Quantix Edge project has delivered the first revenues to the Group as the project advances with the development of a semiconductor design and personalization center in Murcia, Spain, while the proposed Jura project is intended to expand this sovereign semiconductor infrastructure model into Switzerland.
  • Digital Identity and PKI. WISeID, INeS and related PKI services are expected to benefit from growing requirements for trusted identity across humans, machines, AI agents and connected devices.
  • Machine-to-Machine Economy. SEALCOIN and its integration with WISeKey’s identity technologies, secure hardware and distributed-ledger infrastructure are intended to create new transactional applications for autonomous devices and AI agents.
  • Space and QSOC. WISeSat is progressing from satellite technology demonstration toward commercial secure-space infrastructure through the QSOC architecture.
  • Quantum Technologies.  SEALQUANTUM Sovereign Vertical Stack and the proposed Quantisimo platform are intended to consolidate and commercialize complementary capabilities across quantum computing, photonics, post-quantum cybersecurity and trusted infrastructure.

STRATEGIC OUTLOOK: 2027 AND BEYOND

WISeKey is entering a new stage of its corporate development. The Group intends to further develop its specialized technology platforms, with clearer accountability, distinct market positioning and enhanced capital-markets visibility. Building on its existing publicly traded platforms, WISeKey will continue to evaluate opportunities to unlock value through differentiated businesses focused on their respective markets and growth priorities.

Subject to regulatory approvals, shareholder approvals, market conditions and completion of the related transactions, the future structure is expected to include:

  • WISeQey Corp. (Nasdaq and SIX: WQEY): The Group’s parent company will be redomiciled in the British Virgin Islands, with ordinary shares expected to be listed directly on the Nasdaq Global Market and a primary listing on the SIX Swiss Exchange. It will oversee the Group’s Root of Trust, PKI and digital identity businesses.
  • SEALSQ Corp (Nasdaq: LAES): The Group’s post-quantum semiconductor platform, covering the QS7001 secure element, the QVault TPM and the SEALQUANTUM Sovereign Vertical Stack strategy.
  • WISeSat.Space Holdings Corp. (Nasdaq: SAIQ): The Group’s secure satellite and space technology platform, planned to list on Nasdaq through a proposed business combination with Columbus Acquisition Corp. (Nasdaq: COLA).
  • Quantisimo: A combination of selected technologies and investments developed through the SEALQUANTUM Sovereign Vertical Stack ecosystem, creating a vertically integrated platform spanning quantum computing, photonics, quantum-secure infrastructure and related technologies. This is planned to list through a proposed business combination with GIGCapital8 Corp. (Nasdaq: GIW).

The objective is to provide each business with the operational focus, management structure and access to capital required to pursue its respective market opportunity, while preserving technological integration through the WISeKey Root of Trust.

Conference Call

The Company will host a conference call to review its results on Thursday, October 1, 2026, at 9:00 am EDT (3:00 pm CEST). To join, please use the following dial-in numbers:

  • Toll-Free Dial-In Number: 877-445-9755  
  • International Dial-In Number: 201-493-6744  

The webcast of the call can be accessed through the Investor Relations section of WISeKey’s website at www.wisekey.com or by clicking here. An archived version of the call will also be made available.

UNAUDITED ADDITIONAL FINANCIAL & OPERATIONAL DATA

Unaudited Condensed Consolidated Statements of Comprehensive Income/(Loss) [as reported]

  Unaudited 6 months ended June 30,  
USD’000 2026   2025  
         
Net sales 11,434   5,293  
Cost of sales (5,699)   (3,173)  
Depreciation of production assets (257)   (243)  
Gross profit 5,478   1,877  
         
Other operating income 71   82  
Research & development expenses (9,603)   (5,792)  
Selling & marketing expenses (9,474)   (7,393)  
General & administrative expenses (27,351)   (16,090)  
Total operating expenses (46,357)   (29,193)  
Operating loss (40,879)   (27,316)  
         
Non-operating income 9,658   6,964  
Interest and amortization of debt discount and expense (1)   (88)  
Non-operating expenses (5,261)   (1,846)  
Loss before income tax expense (36,483)   (22,286)  
         
Income tax income / (expense) 302   (1)  
Equity in earnings of unconsolidated entities (229)   –  
Net loss (36,410)   (22,287)  
         
Less: Net loss attributable to noncontrolling interests (27,083)   (17,835)  
Net loss attributable to WISeKey International Holding Ltd (9,327)   (4,452)  
         
Earnings / (loss) per Class A Share (USD)        
Earnings / (loss) per Class A Share        
Basic (0.87)   (0.53)  
Diluted (0.87)    (0.53)  
         
Earnings / (loss) per Class A Share attributable to WISeKey International Holding Ltd        
Basic (0.22)   (0.11)  
Diluted (0.22)   (0.11)  
         
Earnings / (loss) per Class B Share (USD)        
Earnings / (loss) per Class B Share        
Basic (8.65)   (5.32)  
Diluted (8.65)   (5.32)  
         
Earnings / (loss) per Class B Share attributable to WISeKey International Holding Ltd        
Basic (2.22)   (1.06)  
Diluted (2.22)   (1.06)  
         

Other comprehensive income / (loss), net of tax:        
Foreign currency translation adjustments (550)   700  
Unrealized gains on debt securities        
Unrealized holding gains arising during the period (1)   23  
Defined benefit pension plans:        
Net gain arising during the period 160   95  
Other comprehensive income / (loss) (391)   818  
Comprehensive loss (36,801)   (21,469)  
         
Other comprehensive income attributable to noncontrolling interests (416)   65  
Other comprehensive income / (loss) attributable to WISeKey International Holding Ltd 25   753  
         
Comprehensive loss attributable to noncontrolling interests (27,499)   (17,770)  
Comprehensive loss attributable
to WISeKey International Holding Ltd
(9,302)   (3,699)  
         

The notes are an integral part of our consolidated financial statements.

Unaudited Condensed Consolidated Balance Sheets [as reported]

  As of June 30,   As of December 31,  
USD’000 2026 (unaudited)   2025  
         
ASSETS        
Current assets        
Cash and cash equivalents 488,953   429,244  
Restricted cash, current 6,311   4  
Accounts receivable, net of allowance for credit losses 8,051   5,109  
Inventories 2,101   2,012  
Prepaid expenses, current 2,033   2,445  
Investment, current 2,449   10,032  
Government assistance 6,613   4,579  
Other current assets 1,994   2,353  
Total current assets 518,505   455,778  
         
Noncurrent assets        
Notes receivable, noncurrent –   31  
Deferred tax credits 4,492   2,364  
Property, plant and equipment net of accumulated depreciation 5,042   3,804  
Intangible and crypto assets, net of accumulated amortization 30,410   21,073  
Operating lease right-of-use assets 5,975   6,366  
Finance lease right-of-use assets 87   126  
Goodwill 20,012   13,973  
Available-for-sale debt securities, noncurrent 128   129  
Equity securities, at cost 19,194   517  
Investment in unconsolidated affiliates 4,262   7,857  
Investment in SAFE 7,000   1,000  
Prepaid expenses, noncurrent 828   1,114  
Other noncurrent assets 443   455  
Total noncurrent assets 97,873   58,809  
TOTAL ASSETS 616,378   514,587  
         
LIABILITIES        
Current Liabilities        
Accounts payable 26,966   19,207  
Notes payable 613   748  
Indebtedness to related parties, current 82   84  
Convertible note payable, current 10   10  
Deferred revenue, current 1,079   93  
Current portion of obligations under operating lease liabilities 683   932  
Current portion of obligations under finance lease liabilities 35   57  
Income tax payable –   3  
Other current liabilities 12,420   14,132  
Total current liabilities 41,888   35,266  

Noncurrent liabilities        
Bonds, mortgages and other long-term debt 724   1,047  
Deferred revenue, noncurrent 1,076   13  
Indebtedness to related parties, noncurrent 1,171   1,324  
Operating lease liabilities, noncurrent 5,227   5,536  
Finance lease liabilities, noncurrent 55   72  
Deferred income tax liability 5,805   4,367  
Employee benefit plan obligation 4,928   4,502  
Other noncurrent liabilities 876   1,311  
Total noncurrent liabilities 19,862   18,172  
TOTAL LIABILITIES 61,750   53,438  
         
Commitments and contingent liabilities        
         
SHAREHOLDERS’ EQUITY        
Common stock – Class A 16   16  
Par value – CHF 0.01 and CHF 0.01        
Authorized – 2,000,880 and 2,000,880 shares        
           Issued and outstanding – 1,600,880 and 1,600,880 shares        
Common stock – Class B 440   440  
Par value – CHF 0.10 and CHF 0.10        
Authorized – 8,281,180 and 8,281,180        
Issued – 4,080,546 and 4,080,546        
Outstanding – 4,024,038 and 4,024,038        
Share subscription in progress –   –  
Treasury stock, at cost (56,508 and 56,508 shares held) (502)   (502)  
Additional paid-in capital 351,740   343,015  
Accumulated other comprehensive income / (loss) 3,451   3,426  
Accumulated deficit (309,806)   (300,479)  
Total shareholders’ equity attributable to WISeKey shareholders 45,339   45,916  
Noncontrolling interests in consolidated subsidiaries 509,289   415,233  
Total shareholders’ equity 554,628   461,149  
TOTAL LIABILITIES AND EQUITY 616,378   514,587  

The notes are an integral part of our consolidated financial statements.

About WISeKey

WISeKey International Holding Ltd (“WISeKey”; SIX: WIHN; Nasdaq: WKEY) is a Swiss-based holding company focused on post quantum cybersecurity, digital identity, space technology and the Internet of Things (IoT). Its operating subsidiaries and technology platforms address distinct parts of this portfolio:

  1. SEALSQ Corp (Nasdaq: LAES) develops secure semiconductors, public key infrastructure (PKI) and post-quantum security products.
  2. WISeSat AG develops space technology and secure satellite communications, particularly for IoT applications.
  3. WISeID provides digital identity, authentication, secure access and digital signing for individuals, enterprises and connected devices.
  4. WISe.ART Corp operates the WISe.ART marketplace, which uses blockchain technology to support trusted digital asset and NFT transactions.
  5. SEALCOIN AG develops decentralized physical infrastructure network (DePIN) technology and the SEALCOIN platform.

Each subsidiary contributes to WISeKey’s mission of securing the internet while focusing on its respective areas of research and expertise. Their technologies seamlessly integrate into the comprehensive WISeKey platform. WISeKey secures digital identity ecosystems for individuals and objects using blockchain, AI, and IoT technologies. With over 1.6 billion microchips deployed across various IoT sectors, WISeKey plays a vital role in securing the Internet of Everything. Trusted by the OISTE/WISeKey cryptographic Root of Trust, WISeKey provides secure authentication and identification for IoT, blockchain, and AI applications. The WISeKey Root of Trust ensures the integrity of online transactions between objects and people. For more information on WISeKey’s strategic direction and its subsidiary companies, please visit www.wisekey.com.

Forward-Looking Statements

This communication contains forward-looking statements concerning WISeKey International Holding Ltd and/or its subsidiaries (collectively, “WISeKey,” “our” or “us”) and its businesses, including statements regarding: our anticipated revenue growth guidance for FY 2026 of 50% to 100%; our ability to convert our commercial pipeline into actual sales; the development, certification, production timing and market for post-quantum cryptography products, including the QS7001 secure element and QVault TPM; the expected completion of the redomiciliation transaction and anticipated trading of WISeQey ordinary shares on Nasdaq and the SIX Swiss Exchange; the proposed business combination between WISeSat and Columbus Acquisition Corp. and related Nasdaq listing; the proposed business combination between Quantisimo and GigCapital8 Corp. and related Nasdaq listing; the SEALQUANTUM Sovereign Vertical Stack strategy and investments, including in Miraex, Quobly, EeroQ and Wecan Group; the Quantum Spatial Orbital Cloud initiative and planned satellite constellation deployment; the proposed Post-Quantum Semiconductor and Cybersecurity Center in the Canton of Jura, Switzerland; the Quantix Edge project in Murcia, Spain; the Geneva Quantum Center of Excellence; the SEALCOIN platform and machine-to-machine transactional infrastructure; the sufficiency of cash to meet liquidity needs; and our ability to attract and retain customers. Forward-looking statements can be identified by terms such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “project,” “will,” “target,” “guidance,” “outlook” and similar expressions.

These statements involve known and unknown risks, uncertainties and other factors that could cause WISeKey’s actual results, financial condition, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. These factors include: our ability to convert our pipeline into actual sales; the ability to realize WISeKey’s anticipated growth strategies and profitability; the development of post-quantum cryptography products and the potential market for such products; WISeKey’s plans for global customer base expansion; the expansion of the WISeSat project and the QSOC initiative; the timing and expected revenues from the commercial deployment of the QS7001 secure element and QVault TPM; the completion of the redomiciliation and the anticipated trading of WISeQey ordinary shares; the completion of the proposed WISeSat and Quantisimo business combinations and related Nasdaq listings; the execution of the SEALQUANTUM Sovereign Vertical Stack strategy; the realization of benefits from our investments in quantum and photonics companies; the development of sovereign semiconductor infrastructure in Jura and Murcia; the deployment of the QSOC satellite constellation; the commercialization of SEALCOIN and related machine-to-machine transactional applications; the sufficiency of cash to meet liquidity needs; WISeKey’s ability to attract and retain customers; changes in economic conditions; market demand and semiconductor industry conditions; and the risks discussed in WISeKey’s filings with the SEC. WISeKey is providing this communication as of this date and does not undertake to update any forward-looking statements as a result of new information, future events or otherwise.

Statements regarding our business pipeline are based on management’s current estimates of potential revenue opportunities and do not represent backlog or contracted revenue. Pipeline conversion is subject to numerous factors including customer validation, technical integration requirements, certification timelines, and market conditions. There can be no assurance that pipeline opportunities will convert to actual sales or that such conversion will occur within anticipated timeframes. The proposed redomiciliation, WISeSat and Quantisimo transactions are subject to definitive agreements, regulatory review, shareholder approvals and customary closing conditions, and there can be no assurance that such transactions will be completed on the anticipated timelines or at all. This press release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities, and it does not constitute an offering prospectus within the meaning of the Swiss Financial Services Act (“FinSA”), the FinSA’s predecessor legislation or advertising within the meaning of the FinSA. Investors must rely on their own evaluation of WISeKey and its securities, including the merits and risks involved. Nothing contained herein is, or shall be relied on as, a promise or representation as to the future performance of WISeKey. Given the risks and uncertainties described herein, you should not place undue reliance on forward-looking statements as a prediction of actual results.

Press and Investor Contacts

WISeKey International Holding Ltd
Company Contact: Carlos Moreira
Chairman & CEO
Tel: +41 22 594 3000
info@wisekey.com 
WISeKey Investor Relations (US) 
The Equity Group Inc.
Lena Cati
Tel: +1 212 836-9611
lena.cati@theequitygroup.com
 

Boston, MA, Sept. 30, 2026 (GLOBE NEWSWIRE) — MiniLuxe Holding Corp. (TSXV: MNLX) (“MiniLuxe” or the “Company”) today announces that its previously announced substantial issuer bid (the “Offer”) for its Class A Subordinate Voting Shares (the “Subordinate Voting Shares”) expired at 5:00 p.m. (Toronto time) on September 24, 2026. The Offer will not be extended, and no Subordinate Voting Shares will be purchased by the Company under the Offer. All tendered Subordinate Voting Shares will be returned to shareholders in accordance with the terms of the Offer.

About MiniLuxe

MiniLuxe Holding Corp. is a Boston-based lifestyle brand and talent empowerment platform transforming the fragmented beauty and self-care industry through its premium service brand, proprietary products, and operating platform. For more than 15 years, MiniLuxe has delivered high-quality nail care, waxing, and esthetic services through a growing network of company-owned, joint venture, and partner-operated studios, completing more than 5 million services to date.

The Company is recognized for its elevated service experience, rigorous hygiene standards, non-toxic products, modern studio design, and commitment to socially responsible labor practices. MiniLuxe’s differentiated model is designed to create better outcomes for both clients and beauty professionals through career development, economic mobility, equity participation, and future ownership opportunities.

MiniLuxe is expanding its reach through a multi-pronged growth strategy that includes new studio development, franchising, and the acquisition and conversion of existing nail salons. By combining a trusted consumer brand, proprietary products, operating expertise, and technology-enabled systems, the Company offers entrepreneurs and operators the opportunity to partner with a proven platform while preserving a strong focus on talent development and service excellence.

Through its growing studio network and product portfolio, MiniLuxe seeks to build the leading trusted brand in beauty and self-care while generating long-term value for clients, talent, and shareholders.

For further information
Christine Mastrangelo
Investor Relations, MiniLuxe Holding Corp.
cmastrangelo@MiniLuxe.com
MiniLuxe.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

This press release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) concerning the Company and its subsidiaries within the meaning of applicable securities laws. Forward-looking information may relate to the future financial outlook and anticipated events or results of the Company and may include information regarding the Company’s financial position, business strategy, growth strategies, acquisition prospects and plans, addressable markets, budgets, operations, financial results, taxes, dividend policy, plans and objectives. Particularly, information regarding the Company’s expectations of future results, performance, achievements, prospects or opportunities or the markets in which the Company operates is forward-looking information. In addition, statements in this press release concerning the proposed completion of the Offer, including the price at which the Company may purchase Subordinate Voting Shares under the Offer and the number of Subordinate Voting Shares to be purchased, may contain forward-looking information. In some cases, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “targets”, “expects”, “budgets”, “scheduled”, “estimates”, “outlook”, “forecasts”, “projects”, “prospects”, “strategy”, “intends”, “anticipates”, “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might”, or “will” occur. In addition, any statements that refer to expectations, intentions, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management’s expectations, estimates and projections regarding future events or circumstances.

Many factors could cause the Company’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking information, including, without limitation, those listed in the “Risk Factors” section of the Company’s filing statement dated November 9, 2021. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements could vary materially from those expressed or implied by the forward-looking statements contained in this press release.

Forward-looking information, by its nature, is based on the Company’s opinions, estimates and assumptions in light of management’s experience and perception of historical trends, current conditions and expected future developments, as well as other factors that the Company currently believes are appropriate and reasonable in the circumstances. Those factors should not be construed as exhaustive. Despite a careful process to prepare and review forward-looking information, there can be no assurance that the underlying opinions, estimates and assumptions will prove to be correct. These factors should be considered carefully, and readers should not place undue reliance on the forward-looking information. Although the Company bases its forward-looking information on assumptions that it believes were reasonable when made, which include, but are not limited to, assumptions with respect to the Company’s future growth potential, results of operations, future prospects and opportunities, execution of the Company’s business strategy, there being no material variations in the current tax and regulatory environments, future levels of indebtedness and current economic conditions remaining unchanged, the Company cautions readers that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which the Company operates may differ materially from the forward-looking statements contained in this press release. In addition, even if the Company’s results of operations, financial condition and liquidity, and the development of the industry in which it operates are consistent with the forward-looking information contained in this press release, those results or developments may not be indicative of results or developments in subsequent periods.

Although the Company has attempted to identify important risk factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other risk factors not presently known to the Company or that the Company presently believes are not material that could also cause actual results or future events to differ materially from those expressed in such forward-looking information. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information, which speaks only as of the date made (or as of the date they are otherwise stated to be made). Any forward-looking statement that is made in this press release speaks only as of the date of such statement.

2

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.